Novartis AG EBITDA 2010-2024 | NVS

Novartis AG EBITDA for the quarter ending September 30, 2024 was $3.627B, a 105.85% increase year-over-year.

  • Novartis AG 2023 EBITDA was 18.152B, a 21.74% increase from 2022.
  • Novartis AG 2022 EBITDA was 14.911B, a 27.56% increase from 2021.
  • Novartis AG 2021 EBITDA was 11.689B, a 28.2% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Novartis AG EBITDA 2010-2024 | NVS

  • Novartis AG 2023 EBITDA was 18.152B, a 21.74% increase from 2022.
  • Novartis AG 2022 EBITDA was 14.911B, a 27.56% increase from 2021.
  • Novartis AG 2021 EBITDA was 11.689B, a 28.2% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$710.1B
Novo Nordisk (NVO)$471.5B
Johnson & Johnson (JNJ)$373.6B
AbbVie (ABBV)$312.7B
Merck (MRK)$250.9B
AstraZeneca (AZN)$203.5B
Pfizer (PFE)$145.4B
Sanofi (SNY)$122.5B
Innoviva (INVA)$1.2B